Quick Answer
Tyra Biosciences, Inc. reported Net Income Loss of -$119.95 million for the year ending 2025.
- Tyra Biosciences, Inc. showed a decrease of -38.7% in Net Income Loss from 2024 to 2025.
- This data is from Tyra Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.47 million | Q2 2020: -$1.84 million | Q3 2020: -$2.34 million | Q4 2020: -$3.69 million | Q1 2021: -$4.21 million | Q2 2021: -$5.51 million | Q3 2021: -$6.64 million | Q1 2022: -$14.83 million | Q2 2022: -$15.10 million | Q3 2022: -$12.51 million | Q1 2023: -$11.88 million | Q2 2023: -$13.27 million | Q3 2023: -$21.15 million | Q1 2024: -$18.19 million | Q2 2024: -$18.70 million | Q3 2024: -$24.02 million | Q1 2025: -$28.15 million | Q2 2025: -$28.10 million | Q3 2025: -$29.87 million.
- Over the full 6 years of available data (2020 to 2025), Tyra Biosciences, Inc.'s Net Income Loss has declined by 1,184.8%.
- Historical annual values: Fiscal year 2025: -$119.95 million | Fiscal year 2024: -$86.48 million | Fiscal year 2023: -$69.13 million | Fiscal year 2022: -$55.33 million | Fiscal year 2021: -$26.29 million | Fiscal year 2020: -$9.34 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: